The FDA has cleared the interleukin (IL)-23 inhibitor tildrakizumab (Ilumya) for the treatment of active psoriatic arthritis (PsA) in adults. Sun Pharma announced the approval on October 30. “As an IL-23 inhibitor administered exclusively by a healthcare provider, Ilumya is now an option for adults with active psoriatic arthritis who are unable to self-administer treatment
Millions of Medicare enrollees who buy stand-alone prescription drug plans will see their average monthly premiums rise by 50% in 2027, a new analysis finds. But enrollees can avoid the average increase — from $34 a month to $51 — by switching to lower-cost plans during the program’s open enrollment period, which runs through Dec.
You don't have permission to access "http://www.medpagetoday.com/washington-watch/washington-watch/123652" on this server. Reference #18.d494d817.1793332899.22e6a54f https://errors.edgesuite.net/18.d494d817.1793332899.22e6a54f
3 min read IF ANYONE CAN MAKE RATTAN hot, it’s Alexander Skarsgård. The actor’s latest film project, about a craftsman who creates a wicker husband (Skarsgård) for a lonely woman (played by Olivia Colman), has been an unlikely hit since its release in theaters last week. But basket weave isn’t the only material Skarsgård’s rocking—he’s
PAGE, Ariz. — Doug Herrera still lives in the house his father built, though his dad died some time ago from cancer. Herrera wonders if that illness could have been linked to pollutants from nearby uranium mining. Now, he worries that a possible new neighbor — a proposed $10 billion mega data center — could
COVID REPORT: Nine New Cases Confirmed Today, Says Joint Information Center
Press release from the Humboldt County Joint Information Center:
The total number of Humboldt County residents confirmed to have contracted COVID-19 now stands at 245, after nine new cases were reported today.
Of the 245 cases, 126 people contracted the virus through contact with another known case, 67 acquired it through out-of-area travel and 34 were a result of community transmission. Eighteen cases remain under investigation.
Today’s alert level stands at three or level orange. Visit humboldtgov.org/dashboard to view the county’s Alert Level Assessment tool.
Humboldt County COVID-19 Data Dashboard: humboldtgov.org/dashboard, Follow us on Facebook: @HumCoCOVID19, Instagram: @HumCoCOVID19, Twitter: @HumCoCOVID19, and Humboldt Health Alert: humboldtgov.org/HumboldtHealthAlert
###
Today
=historic data. All data from the Humboldt County Joint Information Center.
Cases
Case Updates
5 cases under investigation were determined as being acquired through contact to another known case.
2 cases under investigation were determined as being acquired through community transmission.
The FDA has cleared the interleukin (IL)-23 inhibitor tildrakizumab (Ilumya) for the treatment of active psoriatic arthritis (PsA) in adults. Sun Pharma announced the approval on October 30. “As an IL-23 inhibitor administered exclusively by a healthcare provider, Ilumya is now an option for adults with active psoriatic arthritis who are unable to self-administer treatment
Millions of Medicare enrollees who buy stand-alone prescription drug plans will see their average monthly premiums rise by 50% in 2027, a new analysis finds. But enrollees can avoid the average increase — from $34 a month to $51 — by switching to lower-cost plans during the program’s open enrollment period, which runs through Dec.
You don't have permission to access "http://www.medpagetoday.com/washington-watch/washington-watch/123652" on this server. Reference #18.d494d817.1793332899.22e6a54f https://errors.edgesuite.net/18.d494d817.1793332899.22e6a54f
The FDA has cleared the interleukin (IL)-23 inhibitor tildrakizumab (Ilumya) for the treatment of active psoriatic arthritis (PsA) in adults. Sun Pharma announced the approval on October 30. “As an IL-23 inhibitor administered exclusively by a healthcare provider, Ilumya is now an option for adults with active psoriatic arthritis who are unable to self-administer treatment
Millions of Medicare enrollees who buy stand-alone prescription drug plans will see their average monthly premiums rise by 50% in 2027, a new analysis finds. But enrollees can avoid the average increase — from $34 a month to $51 — by switching to lower-cost plans during the program’s open enrollment period, which runs through Dec.
You don't have permission to access "http://www.medpagetoday.com/washington-watch/washington-watch/123652" on this server. Reference #18.d494d817.1793332899.22e6a54f https://errors.edgesuite.net/18.d494d817.1793332899.22e6a54f